BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

eXegenics (EXEG) Responds To Meyers-Weiss Claim


10/19/2005 5:09:27 PM

DALLAS, Dec. 5 /PRNewswire-FirstCall/ -- eXegenics Inc. said today it has received from the Meyers-Weiss Group copies of consents purporting to represent a majority of the outstanding shares of eXegenics voting stock, which would be sufficient to elect a dissident slate of directors. eXegenics said that it is engaging IVS Associates, Inc., independent proxy inspectors, to provide an independent tabulation of the consents and revocations and to report on the results as soon as possible. eXegenics said it would have further comment after it reviews the report from IVS.

Safe Harbor

This release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are subject to certain risks, uncertainties and assumptions that are difficult to predict. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. eXegenics undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Contact: WaLisa M. Davenport eXegenics Inc. (214) 358-2000 William Fiske (Information Agent) Georgeson Shareholder Communications Inc. Banks and Brokers: (212) 440-9800 All Others Call Toll-Free: (800) 964-0733

eXegenics Inc.

CONTACT: WaLisa M. Davenport of eXegenics Inc., +1-214-358-2000, WilliamFiske (Information Agent), Georgeson Shareholder Communications Inc., Banksand Brokers - +1-212-440-9800, All Others Call Toll-Free: 800-964-0733



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES